

Electronic Acknowledgement Receipt

EFS ID:	1371263
Application Number:	09911692
International Application Number:	
Confirmation Number:	8484
Title of Invention:	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
First Named Inventor/Applicant Name:	Darrell R. Anderson
Customer Number:	47553
Filer:	David Laurence Fitzgerald
Filer Authorized By:	
Attorney Docket Number:	27693-01009
Receipt Date:	13-DEC-2006
Filing Date:	25-JUL-2001
Time Stamp:	16:01:04
Application Type:	Utility

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 310
RAM confirmation Number	255
Deposit Account	181260
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	McLaughlin_J_Clin_Oncol_1998.pdf	658216	no	10
Warnings:					
Information:					
2	Foreign Reference	EP00669836B1.pdf	3203030	no	64
Warnings:					
Information:					
3	Foreign Reference	EP00752248A1.pdf	3259343	no	62
Warnings:					
Information:					
4	Foreign Reference	WO08702671A1.pdf	4461507	no	129
Warnings:					
Information:					
5	Foreign Reference	WO08900999A1.pdf	13701064	no	394
Warnings:					
Information:					
6	Foreign Reference	WO09302108A1.pdf	3763449	no	92
Warnings:					
Information:					
7	Foreign Reference	WO00027428A1.pdf	793156	no	21
Warnings:					
Information:					
8	Foreign Reference	WO00027433A1.pdf	588872	no	13
Warnings:					
Information:					
9	Foreign Reference	WO00110460A1.pdf	1010352	no	21
Warnings:					

Information:					
10	NPL Documents	Anderson_Biochem_Soc_Trans_1997.pdf	770969	no	5
Warnings:					
Information:					
11	NPL Documents	Armitage_JCO_1998.pdf	717073	no	16
Warnings:					
Information:					
12	NPL Documents	Berinstein_Ann_Oncol_1998.pdf	809985	no	8
Warnings:					
Information:					
13	NPL Documents	Beychok_1979.pdf	837186	no	22
Warnings:					
Information:					
14	NPL Documents	Buchsbaum_Ca_Res-637_1992.pdf	697714	no	6
Warnings:					
Information:					
15	NPL Documents	Carrasquillo_J_Nucl_Med_1985.pdf	556781	no	3
Warnings:					
Information:					
16	NPL Documents	Chinn_IntJOncol_1999.pdf	1502138	no	13
Warnings:					
Information:					
17	NPL Documents	Chinn_AACR_1999.pdf	64030	no	1
Warnings:					
Information:					
18	NPL Documents	Cogliatti_Sw_Med_Wkly_2002.pdf	254337	no	12
Warnings:					

Information:					
19	NPL Documents	Davis_Clin_Ca_Res_1999.pdf	73837	no	5
Warnings:					
Information:					
20	NPL Documents	Davis_AACR_1998.pdf	214943	no	3
Warnings:					
Information:					
21	NPL Documents	Dillman_J_Clin_Oncol_1994.pdf	2199499	no	20
Warnings:					
Information:					
22	NPL Documents	Grillo-Lopez_Antibody_Eng_r_1994.pdf	32209	no	1
Warnings:					
Information:					
23	NPL Documents	Grillo-Lopez_Ann_Oncol_1996.pdf	69973	no	1
Warnings:					
Information:					
24	NPL Documents	Grillo-Lopez_Antibody_Immunconj_Radiopharm_1995.pdf	400491	no	3
Warnings:					
Information:					
25	NPL Documents	Grillo-Lopez_ASH_1995.pdf	231005	no	3
Warnings:					
Information:					
26	NPL Documents	Grillo-Lopez_Br_J_Hematol_1996.pdf	257609	no	3
Warnings:					
Information:					
27	NPL Documents	Horning_ASH_2002.pdf	660590	no	3
Warnings:					

Information:					
28	NPL Documents	Rituxan_label_1997_GNE_e mb.pdf	607253	no	10
Warnings:					
Information:					
29	NPL Documents	Janakiraman_ASH_1998.pdf	285072	no	3
Warnings:					
Information:					
30	NPL Documents	Kinoshita_J_Clin_Oncol_199 8.pdf	105904	no	1
Warnings:					
Information:					
31	NPL Documents	Maloney_Blood_1997.pdf	147433	no	8
Warnings:					
Information:					
32	NPL Documents	Maloney_ASH_1996.pdf	189985	no	2
Warnings:					
Information:					
33	NPL Documents	Maloney_JCO_1997.pdf	824010	no	10
Warnings:					
Information:					
34	NPL Documents	Maloney_Blood_1994_scan. pdf	975401	no	10
Warnings:					
Information:					
35	NPL Documents	McLaughlin_ASH_1998.pdf	413381	no	4
Warnings:					
Information:					
36	NPL Documents	McLaughlin_Oncol_1998.pdf	831152	no	12
Warnings:					

Information:					
37	NPL Documents	NHL_Path_Class_Proj_Cancer_1982.pdf	1853894	no	24
Warnings:					
Information:					
38	NPL Documents	Pieterz_Immunol_Cell_Biol_1987.pdf	1850524	no	16
Warnings:					
Information:					
39	NPL Documents	Piro_Ann_Oncol_1998.pdf	761296	no	8
Warnings:					
Information:					
40	NPL Documents	Press_Ca_J_Sci_Am_1998.pdf	567818	no	8
Warnings:					
Information:					
41	NPL Documents	Teeling_Blood_2004_scan.pdf	1010308	no	8
Warnings:					
Information:					
42	NPL Documents	Teeling_JImmunol_2006_scan.pdf	1347102	no	10
Warnings:					
Information:					
43	NPL Documents	White_Ann_Oncol_1999.pdf	372194	no	3
Warnings:					
Information:					
44	NPL Documents	White_Ann_Rev_Med_2001_scan.pdf	1143351	no	21
Warnings:					
Information:					
45	NPL Documents	White_Blood_1996_scan.pdf	1363223	no	10
Warnings:					

Information:					
46	NPL Documents	White_Eur_J_Ca_1999.pdf	460990	no	3
Warnings:					
Information:					
47	NPL Documents	Witzig_ASH_1997.pdf	262958	no	3
Warnings:					
Information:					
48	NPL Documents	Witzig_J_Clin_Oncol_1999.pdf	239634	no	11
Warnings:					
Information:					
49	NPL Documents	Witzig_JCO-2453_2002.pdf	628265	no	11
Warnings:					
Information:					
50	NPL Documents	Witzig_ASH_abst-2805_1999.pdf	73036	no	1
Warnings:					
Information:					
51	Sequence Listing	09-911692_SL6.txt	27659	no	0
Warnings:					
Information:					
52		CP1C3_reply-IDS_13Dec06.pdf	206067	yes	30
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Specification		2	3	
	Abstract		4	4	
	Claims		5	7	

	Applicant Arguments/Remarks Made in an Amendment	8	13
	Specification	14	23
	Request under Rule 48 correcting inventorship	24	24
	Information Disclosure Statement (IDS) Filed	25	30

Warnings:

Information:

53	Fee Worksheet (PTO-875)	fee-info.pdf	8390	no	2
----	-------------------------	--------------	------	----	---

Warnings:

Information:

Total Files Size (in bytes):			58345658		
-------------------------------------	--	--	----------	--	--

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.